Key Takeaways
- Dense breast tissue is a common condition which decreases the efficacy of a standard mammogram, requiring doctors to use more advanced screening methods for proper breast cancer detection.
- Insurance coverage gaps and cost-sharing requirements often limit access to advanced screening methods.
- H.R. 6182, the Find It Early Act, aims to remove these barriers by requiring health insurance plans to cover screening and imaging for those at increased risk of breast cancer without cost-sharing, including patients with dense breast tissue.
Dense Breast Tissue and Breast Cancer Detection
The CDC’s current breast cancer prevention guidelines recommend that all women between the ages of 40 and 74 should receive a standard mammogram every two years. While breast cancer screening technology generally has a high sensitivity of around 80%, this ability to detect abnormalities is significantly lowered for those with dense tissue. As a result, basic mammograms can miss a significant portion of breast cancers. Advanced screening and imaging beyond a basic mammogram is often necessary for proper cancer detection in dense breast tissue.
Most insurance plans reflect current CDC recommendations, covering basic mammograms as a preventative service without a copay, deductible, or other cost-sharing. However, more advanced screening and imaging almost always carries some out-of-pocket cost for the patient. Medicare Part B fully covers screening mammograms but requires 20% cost-sharing for diagnostic mammograms after the deductible is met. This is an important distinction because screening mammography falls under the category of preventative care, but advanced screening does not. The FDA now requires patients to be notified if they are determined to have dense breasts and recommends inquiring about additional testing, but patients may not be able to access the required care if their insurance does not cover these tests or does so with cost-sharing.
What is the Find It Early Act?
H.R. 6182, the Find It Early Act, was introduced in November 2025 by Rep. Rosa DeLauro (D-CT) and Sen. Amy Klobuchar (D-MN). It requires that health insurance plans beginning on or after January 1, 2026 must cover breast cancer screening and imaging for individuals with an increased risk of breast cancer, individuals with heterogeneously or extremely dense breast tissue, or those determined to seek screening for other factors without imposing cost-sharing requirements. This would extend the full insurance coverage of basic mammograms mandated by the Affordable Care Act to cover all necessary screening and imaging, including “2D or 3D mammograms, breast ultrasounds, breast magnetic resonance imaging, molecular breast imaging, contrast-enhanced mammography, or other technologies.”
Though both of the Find It Early Act’s sponsors are Democrats, the bill has drawn bipartisan support from cosponsors in both chambers. It follows the concurrent S. 1410, which prohibits cost-sharing on additional breast screenings for individuals with a higher risk of breast cancer.
Benefits and Challenges of Advanced Screening
The Find It Early Act is endorsed by the American College of Surgeons, which commends the bill’s potential to limit late-stage breast cancer diagnoses that carry lower survival rates. In their endorsement justification, ACS cites research on breast cancer survival rates, which has found that breast cancer detected at an early stage can have a 5-year survival rate of 99%, while this rate drops to 33% for cancer detected at an advanced stage. ACS and the broader medical community explains that easier access to advanced screening, facilitated by the Find It Early Act, could detect cancer in dense breast tissue while it is still in an early stage.
However, the Find It Early Act also has the potential to cause quality-of-life problems by endorsing unnecessary procedures. Research performed by the American Academy of Family Physicians suggests that MRI screening supplementing mammography may increase false positives, causing patients unnecessary stress when cancer is not truly present. The study also found that the amount of overall and early-stage cancer found in patients receiving supplementary MRI screening suggests overdiagnosis, meaning that those cancers wouldn’t have gone on to cause harm during the patient’s lifetime. Overdiagnosis could become more prevalent if supplementary screenings were readily available without the strict limitation of medical necessity.
Economic and Financial Considerations
The Find It Early Act carries financial implications at both an individual and societal level. Its alleviation of the cost for advanced screenings allows patients with dense breast tissue to access this care without its typical burdensome cost. Diagnostic mammograms and ultrasounds can cost several hundred dollars while an MRI can cost upwards of $1,000, creating a significant barrier for patients whose insurance doesn’t cover these prices or charges a copay for the procedure. Access to advanced screening also benefits patients by significantly decreasing cancer treatment costs when cancer is diagnosed and detected early. Treatment for stage 3 breast cancer can cost 50% more than treatment for stage 1 breast cancer, and experts estimate that early cancer detection might create $26 billion in annual savings for the U.S. healthcare system.
On the other hand, mandating insurance companies to provide full coverage of advanced screening costs could increase insurance premiums for all customers. State-level policies similar to the Find It Early Act, such as a North Carolina bill forcing insurance companies to cover supplemental breast cancer screenings, have faced controversy because mandating that companies provide services beyond the scope of a standard plan causes them to increase premium costs. This puts some patients at risk of losing financial access to insurance and screenings. Rising premium costs might also make it more difficult for prospective patients to receive health insurance from their employers. A WUNC article on the subject finds that such increases force business owners to decide whether to absorb the cost personally, passing it onto employees, or deciding not to offer health care coverage at all.
Current Legislative Status
The Find it Early Act has been introduced in several recent sessions of Congress but failed to gain serious traction. In the 119th Congress, the bill was referred to the House Subcommittee on Health and the Senate Committee on Health, Education, Labor, and Pensions.
Conclusion
H.R. 6182 requires that insurance plans beginning after January 1, 2026 must cover breast cancer screening and imaging for individuals at increased risk of breast cancer, individuals with dense breast tissue, or those seeking screening for other reasons without imposing co-pay requirements. Though the act seeks to increase breast cancer survival rates and ensure that patients receive affordable treatment, positive reception is tempered by the risks of cancer overdiagnosis and increased insurance premiums. It has failed to gain serious traction thus far, but its aims and the bipartisan support it has received give it a good foundation for success in Congressional committees.
Frequently Asked Questions
What is dense breast tissue?
Some breast tissue contains a higher amount of fibrous tissue and a lower amount of fatty tissue, which can be classified as either heterogeneously or extremely dense tissue. This condition is common and present in around 50% of women.
Why do some patients need screening beyond a standard mammogram?
In addition to conditions like dense breast tissue that make detection with standard mammograms much more difficult, additional risk factors like family history of breast cancer, cancerous symptoms, or presence of the BRCA1 or BRCA 2 gene require more advanced screening to ensure no cancerous or precancerous cell growth goes undetected.
What are the potential benefits of the Find It Early Act?
Supporters have argued that the bill could allow cases of breast cancer in patients with dense breast tissue and other risk factors to be detected earlier through advanced screening methods. Early stage breast cancer is more easily treated and has a very high survival rate.
What critiques have been raised about the Find It Early Act?
Detractors have argued that screenings enabled by the bill make it more likely that there will be higher rates of false positive detection, creating negative outcomes in patient quality of life. The fact that insurance companies would have to pay the costs of advanced screenings is also thought to generate a rise in insurance costs and premiums.